In summary, the results of this study indicated that the expression of VISTA on CD4+ T cells was related to poor prognosis in NSCLC patients and may be used as a prognostic factor for adverse NSCLC outcomes. This evidence concerns the gene CD4 and non-small cell lung carcinoma.